Expression of CX3CR1 associates with cellular migration, metastasis, and prognosis in human clear cell renal cell carcinoma

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 2, 2014, Pages 162-170

  Yao, Xin ^a   Qi, Lifeng ^a   Chen, Xusheng ^a   Du, Jun ^a   Zhang, Zhenting ^a   Liu, Suxiang ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Clear cell renal cell carcinoma; CX3CR1; Fractalkine; Metastasis; Migration; Prognosis

Indexed keywords

CHEMOKINE RECEPTOR CX3CR1; FRACTALKINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE; PROTEIN KINASE B;

ARTICLE; CANCER PROGNOSIS; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CHEMOTAXIS ASSAY; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; WESTERN BLOTTING;

CLEAR CELL RENAL CELL CARCINOMA; CX3CR1; FRACTALKINE; METASTASIS; MIGRATION; PROGNOSIS;

BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINE CX3CL1; CHEMOTAXIS; ENZYME ACTIVATION; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MICROSCOPY, CONFOCAL; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASM METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, CHEMOKINE; TISSUE ARRAY ANALYSIS;

EID: 84892520497     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.12.006     Document Type: Article

References (22)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004, 4:540-550.
3. Zlotnik A. Chemokines in neoplastic progression. Semin Cancer Biol 2004, 14:181-185.
4. Raman D., Baugher P.J., Thu Y.M., Richmond A. Role of chemokines in tumor growth. Cancer Lett 2007, 256:137-165.
5. Reckamp K.L., Strieter R.M., Figlin R.A. Chemokines as therapeutic targets in renal cell carcinoma. Expert Rev Anticancer Ther 2008, 8:887-893.
6. Yao M., Yoshida M., Kishida T., Nakaigawa N., Baba M., Kobayashi K., et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 2002, 94:1569-1575.
7. Marchesi F., Locatelli M., Solinas G., Erreni M., Allavena P., Mantovani A. Role of CX3CR1/CX3CL1 axis in primary and secondary involvement of the nervous system by cancer. J Neuroimmunol 2010, 224:39-44.
8. Jamieson W.L., Shimizu S., D'Ambrosio J.A., Meucci O., Fatatis A. CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res 2008, 68:1715-1722.
9. Shulby S.A., Dolloff N.G., Stearns M.E., Meucci O., Fatatis A. CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Res 2004, 64:4693-4698.
10. Bazan J.F., Bacon K.B., Hardiman G., Wang W., Soo K., Rossi D., et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997, 385:640-644.
11. Yao X., Qian C.N., Zhang Z.F., Tan MH, Kort EJ, Yang XJ, et al. Two distinct types of blood vessels in clear cell renal cell carcinoma have contrasting prognostic implications. Clin Cancer Res 2007, 13:161-169.
12. Herrem C.J., Tatsumi T., Olson K.S., Shirai K., Finke J.H., Bukowski R.M., et al. Expression of Epha2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. Clin Cancer Res 2005, 11:226-231.
13. Halmos G., Schally A.V., Varga J.L., Plonowski A., Rekasi Z., Czompoly T. Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone. Proc Natl Acad Sci USA 2000, 97:10555-10560.
14. Ahn S.Y., Cho C.H., Park K.G., Lee H.J., Lee S., Park S.K., et al. Tumor necrosis factor-alpha induces fractalkine expression preferentially in arterial endothelial cells and mithramycin A suppresses TNF-alpha-induced fractalkine expression. Am J Pathol 2004, 164:1663-1672.
15. Dosquet C., Coudert M.C., Lepage E., Cabane J., Richard F. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?. Clin Cancer Res 1997, 3:2451-2458.
16. Fong A.M., Robinson L.A., Steeber D.A., Tedder T.F., Yoshie O., Imai T., et al. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 1998, 188:1413-1419.
17. Lee S.J., Namkoong S., Kim Y.M., Kim C.K., Lee H., Ha K.S., et al. Fractalkine stimulates angiogenesis by activating the Raf-1/MEK/ERK- and PI3K/Akt/eNOS-dependent signal pathways. Am J Physiol Heart Circ Physiol 2006, 291:2836-2846.
18. Marchesi F., Piemonti L., Fedele G., Destro A., Roncalli M., Albarello L., et al. The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma. Cancer Res 2008, 68:9060-9069.
19. Andre F., Cabioglu N., Assi H., Sabourin J.C., Delaloge S., Sahin A., et al. Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol 2008, 17:945-951.
20. Cambien B., Pomeranz M., Schmid-Antomarchi H., Millet M.A., Breittmayer V., Rossi B., et al. Signal transduction pathways involved in soluble fractalkine-induced monocytic cell adhesion. Blood 2001, 97:2031-2037.
21. Besson A., Davy A., Robbins S.M., Yong V.W. Differential activation of ERKs to focal adhesions by PKC epsilon is required for PMA-induced adhesion and migration of human glioma cells. Oncogene 2001, 20:7398-7407.
22. Imai T., Hieshima K., Haskell C., Baba M., Nagira M., Nishimura M., et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997, 91:521-530.